Key result
End-stage CKD patients on HD and CAPD had decreased total serum NO (14.09 and 10.26 vs 49.65 pmol/μl) and GPx activities compared to healthy controls, but higher plasma SOD activity.
Why the study?
Oxidative stress and endothelial dysfunction may be linked to the higher prevalence of CVD in CKD patients.
Does the type of dialysis (HD vs CAPD) alter antioxidant enzyme activities and NO levels in end-stage CKD patients compared to healthy controls?
Observational (n=37)
No
Does the type of dialysis (HD vs CAPD) alter antioxidant enzyme activities and NO levels in end-stage CKD patients compared to healthy controls?
End-stage CKD patients on hemodialysis or peritoneal dialysis exhibit decreased NO levels and GPx activity alongside increased SOD activity, suggesting an imbalance in oxidative stress markers that may contribute to endothelial dysfunction and cardiovascular disease.
Lower GPx activity and NO levels in dialysis patients signal endothelial dysfunction risk; leaves open whether targeting these markers improves CVD outcomes in CKD.
It consists of a retrospective study with twenty-two individuals diagnosed with DRC: fourteen HD and eight CAPD, followed up in the dialysis center of Antonio Pedro University Hospital (HUAP) of Fluminense Federal University (UFF), between 2015 and 2017. Fifteen healthy control (HC) subjects were included, without diagnosed CKD. Patients with HIV positive, hepatitis A, B, and C, pregnant, cancer, smokers, alcoholics and those exposed to X-rays in the last 3 months, were excluded. Objectives: As oxidative stress and endothelial dysfunction may be linked to the higher prevalence of CVD in CKD patients, we measured the activities of the antioxidants enzymes: SOD and GPx and total NO levels in the plasma and serum of end-stage CKD patients undergoing dialysis therapy, comparing with the HC group. Methods: Quantification of NO levels was performed by fluorometric kit, while activities of SOD and GPx were determined using kinetic methods. Results: We found higher plasma SOD activity in HD (8.58 U/ml) and CAPD (10.14 U/ml), compared to C (3.73 U/ml) group, while GPx activity was decreased in HD (115.38 nmol/h/ml) and CAPD (122.76 nmol/h/ml) groups compared to HC group (275.83 nmol/h/ml). Total serum NO concentration was decreased in HD (14.09 pmol/μl) and CAPD (10.26 pmol/μl), compared to non-CKD patients (49.65 pmol/μl). Conclusion: Decreased total serum NO and GPx activities may lead to endothelial dysfunction and consequently a higher prevalence of CVD in CKD patients.
No takes yet. Share an insight, caveat, or question.
Ribeiro et al. (2024) conducted an observational in Chronic Kidney Disease (n=37). Dialysis therapy (HD and CAPD) vs. Healthy controls without CKD was evaluated on Plasma SOD and GPx activities, and total serum NO levels. End-stage CKD patients on HD and CAPD had decreased total serum NO (14.09 and 10.26 vs 49.65 pmol/μl) and GPx activities compared to healthy controls, but higher plasma SOD activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: